Integrated Laboratory Systems, LLC

Integrated Laboratory Systems, LLC (ILS) is a for-profit scientific research and testing company based in Morrisville, North Carolina, specializing in advanced toxicology and laboratory services for federal agencies. As a subsidiary of Inotiv, Inc., the company provides critical scientific research across multiple domains, with a primary focus on supporting federal agencies like the Environmental Protection Agency (EPA) and National Institutes of Health (NIH) in conducting complex scientific studies and assessments. ILS offers specialized services including mammalian oral exposure studies, histopathology services, genetic toxicology support, and advanced research techniques that help evaluate the potential health and environmental impacts of chemicals and biological substances.

Through its federal contract awards, ILS has consistently performed scientific research and testing services across multiple agencies. The company has been awarded numerous delivery order contracts with the EPA's Office of Research and Development, conducting mammalian oral exposure studies for the Center for Computational Toxicology and Exposure. These contracts, valued from $20,600 to $381,371.82, involve non-Good Laboratory Practice acute oral tolerability studies and chemical exposure pathway assessments. Additionally, ILS has secured contracts with the National Institute of Allergy and Infectious Diseases (NIAID) for histopathology services supporting vaccine and therapeutic efficacy studies, including work on SARS-CoV-2 research. Most of these contracts were not set aside and were competed openly, demonstrating the company's competitive capabilities in scientific research.

ILS has also engaged in federal grant work, most notably through a significant grant from the National Institute of Environmental Health Sciences (NIEHS). The company was awarded a grant (R43ES032751) focused on developing a novel mutagenicity assessment method using human cells as an alternative to traditional in vivo animal testing. This grant aimed to create a new approach methodology that can precisely quantify genetic mutations, potentially revolutionizing regulatory toxicology by reducing reliance on animal testing and providing more human-relevant screening techniques for potential mutations in chemicals, pharmaceuticals, and environmental substances.

The company holds a significant Indefinite Delivery Contract (IDC) with the EPA's Office of Research and Development, a $7.8 million single-award contract set aside for small businesses that runs through January 2027. Under this IDC, ILS has received multiple firm fixed-price delivery orders totaling over $1.5 million to conduct mammalian oral exposure studies at EPA facilities in North Carolina, Ohio, and Cincinnati. The contract supports the EPA's Center for Computational Toxicology and Exposure by generating critical data for evaluating chemical safety and exposure pathways, ultimately contributing to the agency's scientific research and regulatory decision-making processes.